RT Journal Article
SR Electronic
T1 XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2023.11.26.568730
DO 10.1101/2023.11.26.568730
A1 Wang, Qian
A1 Guo, Yicheng
A1 Bowen, Anthony
A1 Mellis, Ian A.
A1 Valdez, Riccardo
A1 Gherasim, Carmen
A1 Gordon, Aubree
A1 Liu, Lihong
A1 Ho, David D.
YR 2023
UL http://biorxiv.org/content/early/2023/12/06/2023.11.26.568730.abstract
AB COVID-19 vaccines have recently been updated with the spike protein of SARS-CoV-2 XBB.1.5 subvariant alone, but their immunogenicity in humans has yet to be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding. We now report that administration of an updated monovalent mRNA vaccine (XBB.1.5 MV) to uninfected individuals boosted serum virus-neutralization antibodies significantly against not only XBB.1.5 (27.0-fold) and the currently dominant EG.5.1 (27.6-fold) but also key emergent viruses like HV.1, HK.3, JD.1.1, and JN.1 (13.3-to-27.4-fold). In individuals previously infected by an Omicron subvariant, serum neutralizing titers were boosted to highest levels (1,504-to-22,978) against all viral variants tested. While immunological imprinting was still evident with the updated vaccines, it was not nearly as severe as the previously authorized bivalent BA.5 vaccine. Our findings strongly support the official recommendation to widely apply the updated COVID-19 vaccines to further protect the public.Competing Interest StatementD.D.H. co-founded TaiMed Biologics and RenBio, and he serves as a consultant for WuXi Biologics and Brii Biosciences and is a board director at Vicarious Surgical. A.G. served as a member of the scientific advisory board for Janssen Pharmaceuticals. The remaining authors declare no conflicts of interest.